CRP and COVID-19: Our aim was to prospectively investigate the safety and efficacy profile of tocilizumab administration at the time point that PaO2/FiO2 < 200 was observed in hospitalized patients with COVID-19 irrespective of CRP and other markers of systemic inflammation.